CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 69 enrolled
Drug / intervention
Humatropedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00266656
NCT00266656Phase 4Completed
CompareCT.gov

Effect of Early Growth Hormone Treatment on Long-term Growth and Skeletal Maturation in Girls With Turner Syndrome

Eli Lilly and Company·interventional·Posted Dec 19, 2005·Updated Mar 31, 2017

In Brief

A Phase 4 clinical trial evaluating Humatrope for Turner Syndrome. Completed, enrolled 69 participants across 9 sites.

Detailed Summary

This is an extension study that will gather long-term data on the effect of early growth hormone (GH) treatment on adult height and other aspects of health and development in girls with Turner syndrome. The main purpose is to determine whether girls who received 2 years of GH treatment before 6 years of age achieve taller adult height than girls who were untreated during this time. The study will also look at middle ear and hearing function, and cognitive and behavioral development. Protocol completion is defined as attainment of height velocity less than or equal to 1.0 cm/year, or bone age greater than or equal to 15 years.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTurner Syndrome
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 19, 2005
Enrollment StartDec 1, 2005
Primary CompletionSep 1, 2015
TodayJul 2, 2026
Enrollment to primary: 9.8 yearsPosted 20.5 years ago

Interventions

Humatropedrug

According to investigator's clinical practice and guided by the approved package insert